Synosis Therapeutics is a small but well-qualified and well-funded drug development company based in South San Francisco, California that is focused on finding new treatments for disorders of the central nervous system (CNS).
Launched in 2007, Synosis is managed by a team with some 180 years of drug development experience, is backed by $32.5 million in funding from high-quality investors and has a rich library of compounds unlike any other company of its size or tenure.
Synosis is leading a new approach in CNS, establishing a better understanding of a drug’s action earlier in development than ever before through the innovative use of medical techniques in small, smart clinical trials designed to establish rapid proof of concept.
Our approach refocuses technology traditionally used in the diagnosis of disease for use in the development of new treatments in CNS to ensure the right amount of drug is getting to the right part of the brain for optimal efficacy.
This innovative use of technology bridges the divide between the potential and the proof of a drug’s action by dramatically reducing the time needed to move from early studies to later phase testing. Synosis’ approach has been validated by a strategic partnership with Roche.
Synosis is focusing initially on the development of five compounds with CNS potential. The company will actively in-license additional compounds with at least one of three characteristics:
- Early clinical trials or a package of data that enable direct progress into clinical trials for a CNS indication
- Developed for a non-CNS indication but with demonstrated potential to treat CNS disorders and/or
- Suggested or demonstrated CNS potential but not a development priority within the current parent company.
Click here to print this page
